若生智能
Drug Database
MM

MMR + varicella zoster vaccine (MMRV zoster vaccine)

✓ Approved

GSK · 疫苗 · 疫苗

什么是 MMR + varicella zoster vaccine？

MMR + varicella zoster vaccine 是一种疫苗，由GSK研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名MMRV zoster vaccine
公司GSK
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, GSK

治疗适应症

MMR + varicella zoster vaccine 针对 3 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsSalmonellosis✓ Approved
Infections and infestationsMeasles✓ Approved
Infections and infestationsVaricella zoster virus infection✓ Approved

相关研究文献

PubMedFrontiers in immunology2026-08-05

Effectiveness of varicella vaccine during a varicella outbreak in a Chinese senior high school: a retrospective cohort study.

Xu Nani N, Wu Liting L, Deng Xuan X, Shu Xin X et al.

To evaluate the vaccine effectiveness (VE) of single-dose and two-dose varicella vaccine (VarV) among senior high school students during a varicella outbreak in China, and provide recommendations for vaccination strategy optimization. A retrospective cohort study was conducted among students in a senior high school in China during a varicella outbreak from July 23 to November 8, 2024. The history of varicella disease, the immunization history of VarV and the incidence during the outbreak among all students in the school were surveyed. Kaplan-Meier methods were used to estimate the cumulative varicella-free survival rate among students with different immunization histories during the outbreak, and the log-rank test was used to compare the survival curves across the five groups. VE was calculated based on attack rates among students with different vaccination doses and intervals since last vaccination. Post-exposure vaccination VE was also assessed. Logistic regression analysis was performed to identify factors associated with varicella infection during the outbreak, and odds ratio (OR) and 95% confidence interval (95% CI) were calculated. Among the 1,862 students present during the outbreak, the overall varicella attack rate was 6.29%. Kaplan-Meier analysis showed significant differences in cumulative varicella-free survival among the different immunization groups (χ² = 297.913, df = 4, P < 0.001). Single-dose varicella vaccine (VarV) coverage was 28.24% (475/1682), and two-dose coverage was 66.23% (1114/1682). Compared with unvaccinated individuals, VE with 95% CI was 32.14% (-54.37%- 70.17%) for 1-dose recipients and 94.74% (88.62%-97.57%) for 2-dose recipients. Among 1-dose recipients, VE was 90.48% (17.22%-98.90%) and 18.68% (-86.86%- 64.61%) for those with an immunization interval ≤10 years and >10 years, respectively. Among 2-dose recipients, VE was 95.94%(90.69%-98.23%) and 92.89%(83.87%-96.87%) for those with an immunization interval ≤6 years and >6 years, respectively. Logistic regression showed that male students had a higher risk of varicella than female students; prior receipt of two doses of VarV significantly reduced the risk of infection; and the risk increased by 1 year for each additional year between the last immunization and exposure to the index case. The VE of post-exposure vaccination was 90.15% (68.53%-96.92%) among unvaccinated students and 94.88% (89.47%-97.51%) among students who had previously received 1 dose. A single dose of varicella vaccine provides limited long-term protection among high school students, whereas a two-dose regimen offers robust and sustained effectiveness. Routine catch-up vaccination and timely post-exposure vaccination are recommended for the effective control of varicella outbreaks in school settings.

PMID 42553282
阅读全文 →
PubMedEnvironmental and ecological statistics2026-08-05

Bayesian spatial modeling of measles outbreak in Texas, USA.

Disanayakage Gihani V W W GVWW, Dey Asim K AK

Measles remains a significant public health concern despite the availability of an effective vaccine, with recent outbreaks in Texas illustrating ongoing vulnerabilities in disease control. This study investigates the spatial distribution of measles incidence during the 2025 outbreak period across Texas counties using a Bayesian Zero-Inflated Poisson model with spatial dependence, incorporating a conditional autoregressive prior. The model accounts for the excess zeros in the data, i.e., counties reporting no cases, while capturing spatial correlations and the effects of demographic and environmental covariates, including MMR vaccination rates, population density, temperature, and precipitation. By applying this modeling framework, we estimate key epidemiological metrics such as the standardized incidence ratio, relative risk, and exceedance probabilities to identify high-risk regions. Results highlight a pronounced spatial concentration of elevated measles risk in northwestern Texas, where low vaccination coverage and other contributing factors have led to a severe outbreak.

PMID 42553737
阅读全文 →
PubMedJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026-08-05

Atopic dermatitis is associated with herpes zoster in adults - A matched cohort study using electronic health records data in England.

Schober Anna K AK, Langan Sinéad M SM, Williams Hywel C HC, Forbes Harriet H et al.

Some atopic dermatitis (AD) treatments have been linked to an increased risk of herpes zoster (HZ). Limited evidence suggests an independent association between atopic dermatitis and herpes zoster. The study aimed to investigate the association between atopic dermatitis and herpes zoster in the UK and to explore the role of treatments in this relationship. We conducted a matched cohort study using routinely collected primary care data from the UK Clinical Practice Research Datalink (CPRD) Aurum database (1997-2023) and applied Cox regression models. Age, behavioral factors, several comorbid diseases and different treatment exposures were included as covariates. Individuals with atopic dermatitis had an adjusted hazard ratio of 1.28 (95% CI: 1.27-1.29) for HZ. Adjustments for different definitions of oral corticosteroid exposure as well as other traditional immunosuppressants led to minimal reductions in the association. The risk of herpes zoster increased with AD severity (aHR for mild AD: 1.22 [95% CI: 1.20-1.23]; aHR for moderate AD: 1.28 [95% CI: 1.27-1.30]; aHR for severe AD: 2.33 [95% CI: 2.22-2.45]). The risk of HZ is increased in individuals with atopic dermatitis, independent of comorbidities and the use of oral corticosteroids or immunosuppressants. This elevated baseline risk is particularly relevant because herpes zoster is also a known adverse effect of newer therapies such as Janus kinase (JAK) inhibitors. These findings may inform vaccination guidelines.

PMID 42552854
阅读全文 →
PubMedPloS one2026-08-05

Performance of PREMM5, clinical criteria, and immunohistochemistry for MMR proteins in genetic risk assessment of Mexican patients with colorectal cancer.

Rodríguez-Olivares José Luis JL, Aguilar-Y-Méndez Dione D, Kimball Tamara N TN, Rivero-García Pamela P et al.

All individuals with colorectal cancer (CRC) should undergo genetic cancer risk assessment given its implications for personalized treatment, surveillance, risk-reduction strategies, and cascade testing. Universal screening using immunohistochemistry (IHC) for mismatch repair (MMR) proteins in tumor tissue, when combined with clinical criteria, is essential for identifying individuals at higher risk for carrying germline pathogenic variants (PVs) in resource limited countries. The spectrum of PVs in cancer susceptibility genes was characterized using NGS multigene panel assays among selected patients with CRC at two centers in Mexico. Germline genetic testing was used as the reference standard to evaluate the diagnostic accuracy of the referral criteria. From September 2018 to October 2024, 208 patients were enrolled. The median age at diagnosis was 45.0 years; 52.4% were women, 48.6% had deficient-MMR CRC, and 38.0% reported family history of CRC. Germline PVs were identified in 32.2% (n = 67); of these, 77.6% (n = 52) had Lynch syndrome (30 MLH1, 14 MSH2, 6 MSH6, and 2 PMS2), while 22.4% (n = 15) harbored PVs in other genes (4 ATM, 3 BRCA1, 3 CHEK2, 2 TP53, 1 BRCA2, 1 BRIP1, and 1 PALB2). Additionally, one individual harbored a monoallelic PV in MUTYH. The Amsterdam II criteria demonstrated the highest specificity (Sensitivity 56.0%, Specificity 91.9%), while the revised Bethesda criteria (Sensitivity 98.1%, Specificity 19.9%) and IHC for MMR proteins (Sensitivity 91.2%, Specificity 68.7%) exhibited high sensitivity. The area under the ROC curve for PREMM5 was 0.822 (95% CI 0.746-0.898). PREMM5, Revised Bethesda criteria and IHC for MMR proteins effectively prioritized patients eligible for germline genetic testing in resource-limited settings. The performance of PREMM5 in this Mexican cohort was comparable to findings reported in validation studies within other populations. Considering the spectrum of PVs identified, employing a multigene panel test is recommended for Mexican patients with CRC.

PMID 42550852
阅读全文 →
PubMedInternational journal of clinical oncology2026-08-05

Clinical utility and cost-effectiveness of universal tumor screening to identify Lynch syndrome in patients with stage II/III colorectal cancer: a prospective observational study in Japan.

Yoshioka Takahiro T, Yamamoto Yasuaki Y, Tsukada Yuichiro Y, Igarashi Ataru A et al.

Universal tumor screening (UTS) for Lynch syndrome (LS) is cost-effective in Western countries; however, cost-effectiveness varies based on the frequency of hereditary diseases and testing costs. This study aimed to clarify the clinical utility and cost-effectiveness of UTS in identifying LS in patients with stage II/III colorectal cancer (CRC) in Japan. This single-center, prospective cohort study evaluated 591 consecutive patients who underwent surgical resection for Stage II/III colorectal adenocarcinoma between 2016 and 2018. Immunohistochemistry (IHC) was used to evaluate mismatch repair (MMR) proteins. In patients with MMR deficiency, BRAF V600E mutational testing and genetic counseling/testing were performed to identify LS based on MMR deficiency patterns. Genetic counseling/testing was also conducted for blood relatives upon request. The cost-effectiveness of implementing UTS was evaluated from the perspective of healthcare payers using a Markov state-transition model, with the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained as the reference value. A total of 40 cases (6.8%) exhibited MMR deficiency; 12 cases (2.0%) had LS, of whom 2 (16.7%) did not meet Amsterdam criteria II or any criteria of the revised Bethesda guidelines. Eleven relatives of five LS probands underwent genetic testing, and six (54.5%) were diagnosed with LS. The ICER for UTS was JPY 0.6 million per QALY gained, substantially below the Japanese threshold of JPY 5.0-6.0 million per QALY. The UTS of LS in patients with stage II/III CRC is a useful and cost-effective tool in Japan.

PMID 42552405
阅读全文 →
PubMedFrontiers in global women's health2026-08-05

Awareness, factual knowledge, attitudes, and acceptability of human papillomavirus vaccination among adult women in Palestine: a cross-sectional study.

Amro Alhareth M AM, Safadi Leen M LM, Fahoum Shahd R SR, Deeb Salahaldeen S et al.

Human papillomavirus (HPV) is a major preventable cause of cervical cancer, yet awareness and uptake of HPV vaccination remain suboptimal in many settings. Evidence regarding women's HPV-related awareness, factual knowledge, and vaccine acceptability in Palestine remains limited. This study assessed awareness, factual knowledge, attitudes, self-reported uptake, willingness, and perceived barriers related to HPV infection and HPV vaccination among adult women in Palestine. A cross-sectional online survey was conducted between October 2025 and February 2026 among women aged ≥18 years residing in Palestine. The questionnaire assessed sociodemographic characteristics, HPV and HPV vaccine awareness, factual knowledge, attitudes, vaccine uptake, willingness to receive or recommend vaccination, and perceived barriers. A 12-item factual knowledge score was calculated, and higher factual knowledge was defined as ≥7 correct responses. Descriptive statistics, subgroup analyses, and multivariable logistic regression were performed. Among 424 adult women included in the final analysis, 220 (51.9%) had heard of HPV and 146 (34.4%) had heard of the HPV vaccine. The mean factual knowledge score was 4.03 ± 2.72 out of 12, and 90 participants (21.2%) had higher factual knowledge. Self-reported HPV vaccine uptake was low (13.0%), whereas willingness to receive the vaccine was higher (55.2%). Lack of awareness (55.8%) and concern about vaccine safety (22.8%) were the most frequently reported barriers among unvaccinated women. In expanded adjusted analyses, prior HPV awareness, prior HPV vaccine awareness, and more supportive HPV-vaccination attitudes were independently associated with higher factual knowledge. Higher factual knowledge and supportive attitudes were associated with self-reported vaccine uptake, while willingness among unvaccinated women was most strongly associated with supportive vaccination attitudes. Adult women in Palestine demonstrated limited HPV-related awareness and low factual knowledge, together with low self-reported HPV vaccine uptake. The gap between willingness and uptake, combined with the predominance of awareness and safety concerns as reported barriers, suggests a need for culturally appropriate education, provider-led counseling, and improved access to reliable HPV vaccine information. Findings should be interpreted cautiously given the cross-sectional design and online convenience sampling.

PMID 42553322
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多MMR + varicella zoster vaccine